You are correct about the CR, but the devil is in the details and we don't have a lot of details. My guess is they will correlate the progression to CR with the in vivo expansion of T-Cells and antigen/epitope spreading. That would be quite convincing. That said, CRs are so rare that more probable than not the T-cells contributed to the response.
I would like to see more defined results info. 56% objective response, but out of those what % stable, what % improved, how much improvement/tumor shrinkage.
How in the hell do you do a third phase pancreatic trial and give a patient who is surely dying a placebo and test that against an experimental treatment for a cancer that has a small success rate of omission. So Phantom is right MRKR treatment of this kind of high mortality rate cancer should stand alone. If it works to a verging degree I would want the treatment alternative then just giving up. Why is this so hard to understand.. It looks like MRKR would have been much better off running phase trials in another country if that was possible. Phantom is that the requirement on third phase to have a placebo group along with a group getting the experimental treatment. If I were a researcher how could you ethically agree to even run the trial. Now I’m pissed because if that’s the case then no wonder it tanked.
News 
Market Data 
Discover 
